New phase 4 data from Vertex Pharmaceuticals revealed that more than 90% of patients recovering from aesthetic or reconstructive surgery remained opioid-free when treated with Journavx (suzetrigine) ...

At the Becker’s Hospital Review 6th Annual Meeting in Chicago, May 7 to 9, William J. Long, MD, of Insall Scott Kelly Institute for Orthopaedics and Sports Medicines in New York, discussed the ...

Postoperative pain management is a significant concern for patients undergoing video-assisted thoracoscopic surgery (VATS). Traditionally, multimodal analgesia (MMA)—combining regional ...

Numerous public health experts and politicians have dubbed the nation’s ongoing opioid overdose and addiction crisis the deadliest drug epidemic in American history. The scope of the crisis will ...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from a Phase 4 study of JOURNAVX® (suzetrigine), a prescription non-opioid pain signal inhibitor for the treatment of ...

Vertex Pharmaceuticals (VRTX) announced data from a Phase 4 study of JOURNAVX, a prescription non-opioid pain signal inhibitor for the treatment of moderate-to-severe acute pain, in adults, that ...

Pain management is a team approach, it takes the client, professionals, and patient to help ensure treatment and management of the pain is possible. So it is important for them to have the right ...

Envision Physician Services’ National Education Director of Anesthesiology Adam Blomberg, MD, FASA, spoke to Becker’s ASC Review about enhanced recovery after surgery protocols, opioids and the future ...

Please provide your email address to receive an email when new articles are posted on . A multimodal postoperative pain regimen increased satisfaction for patients undergoing hand and wrist surgery vs ...

This transcript has been edited for clarity. Jeff Gadsden, MD: Hello, I'm Dr Jeff Gadsden, a professor of anesthesiology at Duke University Hospital in North Carolina. And with me is Dr Eliana ...